SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa). Adamis plans to begin Phase 1/2a clinical studies with APC-100 in men with castrate resistant prostate cancer (CRPR). Each patient will be assessed for toxicity, biochemical responses (Prostate Specific Antigen), radiographic and clinical responses. The study will start at the University of Wisconsin Carbone Cancer Center and then extended to Wayne State University Karmanos Cancer Institute. Both of these Institutions are currently named within “The Prostate Cancer Clinical Trials Consortium” (PCCTC). The PCCTC is made up of a 13 member clinical trial research group sponsored by the Prostate Cancer Foundation and the Department of Defense that capitalizes on their scientific expertise and unique institutional resources in order to rapidly bring new discoveries to prostate cancer patients.
